Evidence map›Paper›PMID 38774075›Full record

ArticleHeliyon2024

Resveratrol protects against diabetic retinal ganglion cell damage by activating the Nrf2 signaling pathway.

Dongqing Yuan, Yingnan Xu, Lian Xue, Weiwei Zhang, Liuwei Gu, Qinghuai Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Observational
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Multi-omics in exploring the pathophysiology of diabetic retinopathy.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dongqing YuanDepartment of Ophthalmology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Women and Children Health Hospital, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China.
Yingnan XuDepartment of Ophthalmology, The Affiliated Eye Hospital of Nanjing Medical University, Nanjing, China.
Lian XueDepartment of Neurology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China.
Weiwei ZhangDepartment of Ophthalmology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Women and Children Health Hospital, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China.
Liuwei GuDepartment of Ophthalmology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Women and Children Health Hospital, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China.
Qinghuai LiuDepartment of Ophthalmology, Jiangsu Province Hospital, The First Affiliated Hospital with Nanjing Medical University, Jiangsu Women and Children Health Hospital, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Oxidative stress-induced retinal neurodegenerative changes are among the pathological alterations observed in diabetic retinopathy. Resveratrol (RSV), a polyphenolic compound with diverse pharmacological effects, has shown preventive qualities in several neurodegenerative illnesses, including anti-inflammatory, anti-aging, and antioxidant benefits. However, its therapeutic efficacy in diabetic retinal neurodegeneration has not yet been thoroughly elucidated. Our study aimed to explore the protective mechanisms and therapeutic benefits of RSV on diabetic retinal neurodegeneration alterations. Materials and methods: Using streptozotocin, we created a diabetic mouse model and conducted visual electrophysiological examinations on mice from the normal group, diabetic group, and diabetic group treated with RSV. Retinas were harvested for histological staining. Additionally, primary retinal ganglion cells cultured in high glucose conditions were used to assess malondialdehyde (MDA) levels and superoxide dismutase (SOD) levels upon siRNA-mediated nuclear factor erythroid 2-related factor 2 (Nrf2) interference. Protein levels of Nrf-2, heme oxygenase-1 (HO-1), and transcriptional levels of them were also measured. Results: We demonstrated that RSV significantly improved the retinal morphology and function in the diabetic retinopathy model mice. The treated mice exhibited notable improvements in visual electrophysiology, with a significant reduction in retinal ganglion cell apoptosis. Following RSV treatment, the high glucose-cultured ganglion cells demonstrated a considerable rise in SOD levels and a substantial drop in MOD. Moreover, the protein expression of solute carrier family 7 member 11 (SLC7A11) and Nrf2 significantly increased. RT-PCR and Western blot results indicated a significant attenuation of RSV's therapeutic effects upon Nrf2 inhibition. Conclusion: Our findings suggest that RSV may reduce oxidative stress levels in the retina and inhibit retinal ganglion cell apoptosis via reducing the Nrf2/HO-1 pathway, which lessens the harm that excessive glucose causes to the retina.

Indexed as

ApotosisDiabetic retinopathyNrf2/HO-1 pathwayOxidative stressResveratrolRetinal ganglion cells

Identifiers

PMID38774075
PMCPMC11107105

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.